|Meeting Highlights in Myelofibrosis from the ASH Annual Meeting|
CME, CPE, CNE
Andrew Kuykendall, MD, Haris Ali, MD, and Stephen T. Oh, MD, PhD
|Release Date: May 09, 2023|
Expiration Date: May 09, 2024
In this activity, three myelofibrosis experts discuss how new advances and research should be applied in clinical practice using updated data presented at the ASH annual meeting. Determining the optimal course of action following JAK inhibitor treatment failure/intolerance/disease progression is extremely difficult because there is no standard course of action. Fortunately, research is identifying new agents that appear to be effective either alone or when combined with ruxolitinib in newly diagnosed and/or progressing patients.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Constellation Pharmaceuticals Inc., A MorphoSys Company and Incyte Corporation.
|Begin, Earn CreditView Only, No Credit|